Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
24/10/17 OPEDED�AT 1519.50 CLOSED AT 1512.00 DOWN 7.5P 25/10/17 OPENED .AT 1512.00 CLOSED AT 1429.00 DOWN 83P 26/10/17 OPENED AT 1411.00 CLOSED .AT 1380.00 DOWN 31 P 27/10/17 OPENED AT 1370.50 CLOSED AT 1366.50 DOWN 4P 30/10/17 OPENED AT 1363.50 CLOSED AT 1372.50 UP 9P 31/10/17 OPENED AT 1369.50 CLOSED AT 1357.50 DOWN 12 P 1/11/17 OPENED AT 1355.00 CLOSED AT 1351.50 DOWN 3.5P 2/11/17 OPENED AT 13.44.00 CLOSED AT 1358.50 UP 14.5P 3/11/17 OPENED AT 1358.50 CLOSED AT 1361.00 UP 2.5P 6/11/17 OPENED AT 1350.00 CLOSED AT 1360.50 UP 10.50 P 7/11/17 OPENED AT 1363.00 CLOSED AT 1343.00 DOWN 20P WEDNESDAY 8/11/17 OPEDED AT 1345.00 CLOSED AT 1362.50 UP 17P THURSDAY EX-DIV DAY OPENED AFTER -19P DIV ADJUSTMENT AT 1349.50 DOWN 13P DAY HIGH WAS APPROX. 1365.50 CLOSED AT 1346.50 DOWN 3 P ON DAY FRIDAY 10/11/17 OPENED AT 1349.00 CLOSE/NOW 1318.00 DOWN 31P ON DAY SO BETWEEN TUESDAY 24/10/17 PRICE WAS 1519.50 AND TODAY FRIDAY 10/11/17 PRICE WAS 1318.00 = A DROP OF 201.5P Top Five Mutual Fund Holders: VA CollegeAmerica Inc. Fund of America holds 60.5 million shares, or a 1.2 percent stake, as of June 30, 2017. It recently shed 2.2 million shares. That accounts for 1.23 percent of the fund�s total net assets. Vanguard Total Intl. Stock Index holds 61.5 million shares, or 1.25 percent stake, as of Aug. 31, 2017. It recently added 671,500 shares. VA CollegeAmerica Cap. Inc Bldr holds 28.6 million shares, or a 0.58 percent stake, as of June 30, 2017. It recently dropped about 7 million shares. That accounts for about 0.6 percent of its net assets. Vanguard Developed Markets Idx Admiral holds 24.5 million shares, or a 0.5 percent stake, as of Aug. 31, 2017. That accounts for about 0.5 percent of its total assets. Federated Strategic Value Dividend A holds 18.2 million shares, or a 0.37 percent stake, as of June 30, 2017. That accounts for about 2.8 percent of its total assets. Top Five Institutional Holders: Vanguard Group holds 103.9 million shares, or a 2.1 percent stake as of Aug. 31 2017. That accounts for 0.5% of its total assets. It recently shed 6.3 million shares. Capital Research and Management Company holds 93.7 million shares, or a 1.9 percent stake in Glaxo as of June 30, 2017. It recently shed 12.6 million shares. BlackRock Fund Advisors holds 73.4 million shares, or a 1.5 percent stake as of Sept. 28, 2017. It recently added 753.4 million shares. Fidelity Management and Research Co. holds 58.5 million shares, or a 1.2 percent stake in Glaxo as of July 31, 2017. BlackRock Investment Management holds 38.6 million shares, or a 0.8 percent stake as of August 31, 2017. That represents about 2.1 percent of its total assets.
24/10/17 OPEDED������������������������������..AT 1519.50 CLOSED ������������������������������������.AT 1512.00 DOWN 7.5P 25/10/17 OPENED ������������������������������.AT 1512.00 CLOSED������������������������������������..AT 1429.00 DOWN 83P 26/10/17 OPENED ������������������������������.AT 1411.00 CLOSED ������������������������������������ .AT 1380.00 DOWN 31 P 27/10/17 OPENED ������������������������������.AT 1370.50 CLOSED ������������������������������������..AT 1366.50 DOWN 4P 30/10/17 OPENED ������������������������������.AT 1363.50 CLOSED�������������������������������������AT 1372.50 UP 9P 31/10/17 OPE
24/10/17 OPENED������������������������������..AT 1519.50 CLOSED ������������������������������������.AT 1512.00 DOWN 7.5P 25/10/17 OPENED ������������������������������.AT 1512.00 CLOSED������������������������������������..AT 1429.00 DOWN 83P 26/10/17 OPENED ������������������������������.AT 1411.00 CLOSED ������������������������������������ .AT 1380.00 DOWN 31 P 27/10/17 OPENED ������������������������������.AT 1370.50 CLOSED ������������������������������������..AT 1366.50 DOWN 4P 30/10/17 OPENED ������������������������������.AT 1363.50 CLOSED�������������������������������������AT 1372.50 UP 9P 31/10/17 OPE
Glaxo bid for Pfizer arm a bad idea, says Jefferies Speculation that GlaxoSmithKline (GSK) may bid for Pfizer�s consumer business has undermined confidence in the pharma giant�s dividend, says Jefferies. Analyst Jeffrey Holford retained his �buy� recommendation but lowered the target price from �17.00 to �15.40 on the stock, which fell 1.1% to �13.57 yesterday. �Management has undermined confidence in the dividend,� he said. �Investors fear it could be sacrificed to acquire Pfizer�s consumer business. We think the dividend is too important to too many GSK shareholders for management to pursue this strategy.� He added that recent consumer deals �have not been successful�. �Despite our reservations on GSK, the stock price has fallen too much in our view and we believe it can rebound to �15.40 on earnings support alone.�
30/10/2017 GlaxoSmithKline plc 12.4% Potential Upside Indicated by Jefferies International analyst believes there is a potential upside of 12.4%�from the opening price of 1369.5 GBX. Over the last 30 and 90 trading days the company share price has decreased 151 points and decreased 146.5 points respectively. The 52 week high for the stock is 1724.5 GBX while the 52 week low for the share price is 1351 GBX. GlaxoSmithKline plc has a 50 day moving average of 1,505.27 GBX and the 200 Day Moving Average price is recorded at 1,598.02.�There are currently 4,918,630,965 shares in issue with the average daily volume traded being 8,260,669. Market capitalisation for LON:GSK is �67,508,209,995 GBP. http://www.***************************/glaxosmithkline-plc-12-4-potential-upside-indicated-by-jefferies-international/412738965
GSK INVESTORS EVENT JULY 2017 EMMA WALMSLEY STATES AFTER 40.40 MINUTES OUT OF A 43 MINUTE SPEECH PRIORITIEY 2 SHAREHOLDERS RETURNS, 80p DIVIDEND 2017 And intention of 80p IN 2018 AND ON https://www.youtube.com/watch?v=XJSWx31V3so
OCTOBER 25, 2017 11:10 AM A newly approved shingles vaccine could become the nation�s primary defense against the painful skin disease after the new medication was endorsed Wednesday by scientific advisers to the U.S. Centers for Disease Control. GlaxoSmithKline�s new vaccine, Shingrix, was approved Friday by the U.S. Food and Drug Administration. It�s only the second shingles vaccine approved in this country, along with Merck�s Zostavax, which has been in use since 2006. Where the FDA approves medications for public use based on efficacy and safety, the CDC endorses preferred drugs. On Wednesday, the CDC�s Advisory Committee on Immunization Practices met in Atlanta, Ga., and recommended that the CDC endorse Shingrix over Zostavax, and also recommended Shingrix shots for Americans aged 50 and above. Shingles affects 1 in 3 Americans in their lifetime, and strikes an estimated 1 million Americans each year. The disease is caused by the Varicella Zoster virus, the same virus that causes chickenpox. If you�ve had chickenpox, the virus can lie dormant for decades and become active later in life, causing a painful, itchy rash and debilitating swelling and blisters. TO READ MORE CLICK http://www.newsobserver.com/news/business/article180782786.html
27 October 2017 ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV Data for investigational attachment inhibitor presented at the 16th European AIDS Conference in Milan Issued: London, UK ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced results from the phase III BRIGHTE study of fostemsavir in heavily treatment-experienced (HTE) patients with HIV-1 infection. Following one week of treatment, HTE patients receiving fostemsavir added to a failing regimen experienced a greater reduction in HIV-1 viral load compared to patients receiving placebo, demonstrating statistical superiority of fostemsavir over placebo (0.79 log10 c/mL vs 0.17 log10 c/mL; p<0.0001).
Reported by the Times today Glaxosmithkline after raising the prospect of parting with $15 billion to bolster it's con-health business by declaring it's interest in Pfizer's consumer business . This triggered concerns in the city about a possible dividend cut even though GSK has said that it plans to maintain the dividend next year, the sp dropped 5.5% me , I think it is time EMMA WALMSLEY made it clear to the city/share holders the companies intentions on the future of the dividend to stop this uncertainty sp must be down somewhere near 10% this week crazy
ex-divined on Thursday 9th NOVEMBER 19 pence paid on 11th JANUARY 2018 buy the shares up to close of business Wednesday 8th NOV. and get the dividend and if you like sell the shares on the ex-dividend day Thursday and still get the dividend but note the share price will be adjusted down by the dividend payment 19p before the market opens on THURSDAY 9th
http://www.morningstar.co.uk/uk/news/162294/glaxo-dividend-cut-unlikely-say-analysts.aspx
25 October 2017 GSK delivers Q3 sales of �7.8 billion, +4% AER, +2% CER Total EPS 24.8p, +49% AER, +46% CER; Adjusted EPS 32.5p, +3% AER, flat CER 25 October 2017 CDC�s Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up Committee recommends immunization for up to 62 million additional adults in the US .............................................................................................................................................. 62 MILLION 23 October 2017 Shingrix approved in the US for prevention of shingles in adults aged 50 and over Pooled clinical trial results showed > 90 percent efficacy across all age groups 18 October 2017 GSK receives World Health Organization Prequalification for Synflorix pneumococcal vaccine four-dose vial The World Health Organization (WHO) has awarded prequalification for the new four-dose vial prese... Read more 13 October 2017 GSK announces first approval of Shingrix in Canada ME HOW MANY MILLION The only shingles vaccine to achieve ≥90% efficacy in adults aged 50 and over WHEN INVESTORS WORKOUT THE UP SIDE TO GSK WE MAY SEE A REVERSE OF -6%/7% SLIDE I MITE EVEN BUY SOME MORE AT THIS PRICE.
Glaxo is close to launching three new products, including shingles vaccine Shingrix and its once-daily inhaler for lung disease, both of which have secured regulatory approval. Having committed to pay 80p a share in dividends per year until 2018, the company will also announce a new dividend policy next year. Deutsche Bank thinks the dividend is secure, but believes "likely pressures on ViiV growth [HIV business] and a need to invest behind the pipeline limit scope for upside to this".
At least three buyout groups seen advancing in Unilever spreads auction: A team comprising Bain Capital and Clayton Dubilier & Rice along with private equity rivals KKR and Apollo are expected to move to the second round an auction for Unilever�s margarine and spreads business while two other private equity groups are no longer in the fray, sources said. - Reuters
EX-DIVIDEND ON THURSDAY 2nd NOVEMBER 2017 DIVIDEND PAYMENT OF 31.99p FOR EACH SHARE HELD UP TO CLOSE OF BUSINESS WEDNESDAY 1st NOVEMBER, PAYMENT WILL BE ON THE 13th DECEMBER 2017 YOU CAN BUY THE SHARES UP TO THE CLOSE OF BUSINESS WED 1st AND STILL GET THE DIVIDEND YOU CAN SELL THE SHARES ON THE EX-DIVIDEND DAY AND STILL GET THE DIVIDEND..
1. ftse at a all time high and nobody really knows where it's going between now and the end of the year 2. ULVR sp this year 30/01/17 � 32.24 03/04/17 �39.22 11/08/ 17 �43.74 25/09/17 �42.69 today �41.27. I personally am going to wait and see what happens between now and mid December.
that's a fare comment to my post, the idea was to get new investors to think before jumping in as i have done in the past, caution is not a bad word, or when in doubt don't, is another. yes i agree it's just a dip for Unilever but are we at the bottom yet ?